Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iX BiopharmaSGX:42C +0.92%36 Pretax Margin % is -57.58% as of Mar. 2026. GuruFocus rates SGX:42C with a GF Score™ of 36/100 and a GF Value™ of S$0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 960 Drug Manufacturers companies, iX Biopharma ranks worse than 88.44% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. iX Biopharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was S$-0.92 Mil. iX Biopharma's Revenue for the
three
months ended in Mar. 2026 was S$1.59 Mil. Therefore, iX Biopharma's pretax margin for the quarter that ended in Mar. 2026 was -57.58%.
The historical rank and industry rank for iX Biopharma's Pretax Margin % or its related term are showing as below:
SGX:42C'
s Pretax Margin % Range Over the Past 10 Years
Min: -6193.09 Med: -165.86 Max: -28.49
Current: -68.3
SGX:42C's Pretax Margin % is ranked worse than 88.44% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.02
vs SGX:42C: -68.30
iX Biopharma (SGX:42C) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
iX Biopharma Pretax Margin % Related Terms
iX Biopharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for iX Biopharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:42C vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where iX Biopharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iX Biopharma (SGX:42C) has a Pretax Margin % of -57.58% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on iX Biopharma and its competitors. According to the industry distribution chart, iX Biopharma ranks #849 out of 960 companies in the Drug Manufacturers industry, placing it in the top 88.4%.
Is iX Biopharma's Pretax Margin % too high?
iX Biopharma's current Pretax Margin % is -57.58%. Based on the distribution chart, iX Biopharma ranks #849 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, iX Biopharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, iX Biopharma ranks #849 out of 960 companies for Pretax Margin %. This places iX Biopharma in the lower half of its industry. The industry median Pretax Margin % is 7.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.02, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on iX Biopharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iX Biopharma's current Pretax Margin % is -57.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
Based on GuruFocus' analysis, iX Biopharma (SGX:42C) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.03, compared to a current price of S$0.55 — trading 1733.3% above its estimated fair value. The current Pretax Margin % is -57.58%. iX Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Pretax Margin % is -57.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iX Biopharma (SGX:42C) Overvalued in 2026?
Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued.
The current stock price of S$0.55 is trading 1733.3% above its estimated GF Value™ of S$0.03.
GuruFocus considers iX Biopharma to be Significantly Overvalued.
Key valuation signals for SGX:42C:
Pretax Margin %: -57.58%
GF Value™: S$0.03 vs. price of S$0.55 (1733.3% above fair value)
No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score
Get the complete analysis for SGX:42C
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:42C has been successfully added to your 
